|
KMID : 0311120220630070701
|
|
Yonsei Medical Journal
2022 Volume.63 No. 7 p.701 ~ p.705
|
|
|
Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa
|
|
Kwak Ji-Yong
Kim Hae-Rang
Byeon Suk-Ho
|
|
|
Abstract
|
|
|
|
Here, we report early treatment outcomes of gene therapy for early onset retinitis pigmentosa (RP) (Leber congenital amaurosis)associated with biallelic RPE65 mutation in a 30-year-old female patient. Initially, her visual acuity (VA) was 20/200, and her visu al field (VF) was severely constricted to the center in the left eye. Her electroretinography showed nearly extinct signals. Full-fieldstimulus threshold test (FST) revealed diminished dark-adapted light sensitivity. Voretigene neparvovec-rzyl (VN) is the first invivo viral gene therapy agent to be approved. At 3 months after subretinal injection of VN in the left eye, VA, VF, and FST showedsustained improvement. She did not exhibit any signs of adverse effects from the treatment. Gene therapy for RP proved to be aneffective and safe treatment in an advanced case of RPE65-associatied early onset RP.
|
|
|
KEYWORD
|
|
|
Retinitis pigmentosa, leber congenital amaurosis, hereditary eye disease, gene therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|